A recent study has demonstrated that Biosimilar Denosumab (Denuril), manufactured by Alkem, is comparable in efficacy to the original Denosumab in treating postmenopausal osteoporosis. Denosumab is a monoclonal antibody that helps to prevent bone loss by inhibiting the activity of osteoclasts, which are cells that break down bone. It is commonly used to treat osteoporosis in postmenopausal women.
The study, published in the Journal of Bone and Mineral Research, involved 354 postmenopausal women with osteoporosis who were randomized to receive either Biosimilar Denosumab (Denuril) or the original Denosumab. The participants received 60mg of the study drug every six months for one year.
The results of the study showed that both Biosimilar Denosumab (Denuril) and the original Denosumab significantly increased bone density in the spine and hip, and reduced the risk of vertebral fractures, a common complication of osteoporosis. The efficacy of the two medications was comparable, with no significant differences observed between the two groups.
The study also found that both medications were well tolerated, with similar levels of adverse events reported in both groups. The most common side effects were mild and included injection site reactions, pain, and infections.
The authors of the study concluded that Biosimilar Denosumab (Denuril) is a viable option for the treatment of postmenopausal osteoporosis, offering similar efficacy and safety to the original Denosumab. This could lead to cost savings and increased access to treatment for patients, making it a valuable addition to the treatment options for osteoporosis.
Overall, the study provides reassuring evidence for the use of Biosimilar Denosumab (Denuril) in the treatment of postmenopausal osteoporosis, and supports its adoption as a viable alternative to the original Denosumab.